drugset / Trial / NCT01289678
Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
NaSingle-groupOpen-labelTreatment
Summary
Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.
Timeline
- Start
- 2006-07
- Primary completion
- 2016-08-31
- Completion
- 2016-08-31
Outcome
Outcome not reported
Stopped (Enrollment): “Unable to meet accrual goals”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 1.8e+07 unknown | Intravenous |
| Background | Famotine | Small molecule | 20 mg | Intravenous |